Disease Spotlight Increase collaboration to widen access to DMD drugs, trials ... When it comes to fighting a rare disease like Duchenne muscular dystrophy (DMD), it’s a matter of strength in numbers.
News Pfizer axes development of Duchenne muscular dystrophy antib... Pfizer has axed trials of its domagrozumab antibody for Duchenne muscular dystrophy (DMD), after it failed against efficacy targets.
News Sarepta dives deeper into gene therapy Sarepta Therapeutics has handed $30 million to Lacerta in exchange for a group of gene therapies, including a Pompe disease candidate.
Slider in home page He ain’t heavy – learning about a sibling’s DMD diagnosis It’s common for patients to want to know more about what’s causing them to be ill and their DMD diagnosis and it’s the same for their families – however long that road may be.
Partner Content Partner Content An experimental gene therapy for DMD shows positive results Cell & Gene Therapy 2018
R&D Precision, speed, impact: Evolving mass spectrometry for med... MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face